{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Azacytidine+%285-aza%29&page=20", "query": { "intervention": "5-Azacytidine (5-aza)", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 477, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Azacytidine+%285-aza%29&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Azacytidine+%285-aza%29&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T20:56:37.560Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02269280", "title": "Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Azacitidine (AZA) Days 1 - 3", "type": "DRUG" }, { "name": "Decitabine (DAC)", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" }, { "name": "Azacitidine (AZA) Days 1 - 5", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2014-10-13", "completion_date": "2024-07-25", "has_results": true, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 6, "location_summary": "Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269280" }, { "nct_id": "NCT02147873", "title": "Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Chronic Myelomonocytic Leukemia (CMML)" ], "interventions": [ { "name": "birinapant", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TetraLogic Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2014-06", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-10-20", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 46, "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 39 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02147873" }, { "nct_id": "NCT01155583", "title": "Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "azacitidine", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "DNA methylation analysis", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" }, { "name": "bone marrow aspiration", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2010-06", "completion_date": "2018-11-06", "has_results": true, "last_update_posted_date": "2020-11-16", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01155583" }, { "nct_id": "NCT02316964", "title": "Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "decitabine", "type": "DRUG" }, { "name": "natural killer cell therapy", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Sumithira Vasu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-04-21", "completion_date": "2019-12-20", "has_results": false, "last_update_posted_date": "2020-03-09", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02316964" }, { "nct_id": "NCT04086238", "title": "Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpiDestiny, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 46, "start_date": "2019-10-08", "completion_date": "2019-11-30", "has_results": false, "last_update_posted_date": "2020-01-22", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04086238" }, { "nct_id": "NCT01305499", "title": "A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Entinostat days 3, 10", "type": "DRUG" }, { "name": "5AC", "type": "DRUG" }, { "name": "Entinostat days 10,17", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hetty Carraway", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 52, "start_date": "2011-07-01", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-05-28", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Cleveland, Ohio", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01305499" }, { "nct_id": "NCT00503984", "title": "A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Pain" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "GADD45α methylation and expression analysis", "type": "GENETIC" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "GENETIC" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": 22, "start_date": "2007-05", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-06-09", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00503984" }, { "nct_id": "NCT04493138", "title": "Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome", "Recurrent Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-07-21", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493138" }, { "nct_id": "NCT00085293", "title": "Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Papillary Thyroid Cancer", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Papillary Thyroid Cancer", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Papillary Thyroid Cancer" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Iodine I 131", "type": "RADIATION" }, { "name": "Recombinant thyrotropin alfa", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "Positron emission tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2004-05", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 3, "location_summary": "Aurora, Colorado • Columbus, Ohio • Houston, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085293" }, { "nct_id": "NCT06445907", "title": "Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Q702", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2025-02-12", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-15T20:56:37.560Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445907" } ] }